Breaking developments in psychiatric research and updates from Psychopharmacology Bulletin.
Abstract Objective Adult ADHD assessments have increased sharply in recent years, yet the diagnostic yield and predictors of confirmed ADHD among assessment-seeking individuals remain insufficiently understood. This study aimed to examine the sociodemographic and clinical characteristics of adults self-referred…
Read MoreGLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, a new study shows.…
Salt Lake City, UT — Lipocine Inc. announced positive progress in its pivotal phase 3 clinical trial evaluating oral brexanolone (LPCN 1154) for the treatment of postpartum depression…
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti–microtubule binding region tau (anti–MTBR-tau) antibody…
What if the next leap in psychiatric treatment doesn’t come from tweaking dopamine or serotonin, but from reengineering the immune system, harnessing neuroplasticity, or refining orexin antagonism? In…
By mid-2025, the psychopharmacology landscape feels paradoxical: on one hand, deeply familiar challenges — slow response, heterogeneity, side effects — still dominate clinical reality. On the other, a…
What if the next leap in psychiatric therapeutics comes not from entirely new receptors, but from smarter targeting—or smarter delivery? From LSD-derived anxiety relief to once-weekly schizophrenia pills,…
